Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Post by jopatcloon Jun 20, 2024 1:08pm
44 Views
Post# 36098273

Join us 25 in downtown Vancouver for Next Evolution in Healt

Join us 25 in downtown Vancouver for Next Evolution in Healt
Next Tuesday the 25th...
 (Hugh MacNaught, President and CEO, Ventripoint Diagnostics Limited)
Panel: Accelerating AI Startups in Canadian Health Care
BC is developing applications of AI and digital health with global impact. How can we accelerate the growth of these firms at the same time as we use AI to improve health services in Canada?
Maryam Sadeghi, CEO & Co-Founder, MetaOptima
Lloyd Jura, Professor, New York Institute of Technology
Hugh MacNaught, President and CEO, Ventripoint Diagnostics Limited
Tiffany Chui, Vice President, Communications, AbCellera‍
Panel moderator: Dr. Alexandra T Greenhill, CEO, CareTeam Technologies
Join us on June 25 in downtown Vancouver for The Next Evolution in Health: Our AI & Health Data Opportunity. Explore how health data stewardship, AI, and life science research can revolutionize Canadian health services and elevate our global profile. Connect with top health and life science executives, researchers, and technology leaders.
 
The final agenda is complete — get your tickets now and be part of this transformative event.
Check it out https://lnkd.in/ePRnDS3N
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities